Dr. Arti Hurria is a geriatrician and oncologist. She completed the Harvard Geriatric Fellowship Program, followed by a hematology-oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Subsequently, she joined the faculty at MSKCC, where she served as co-Principal Investigator on an institutional NIH P20 grant “Development of an Aging and Cancer Center.” In 2006, Dr. Hurria joined City of Hope as Director of the Cancer and Aging Research Program and an Associate Professor, where she is actively involved in both patient care and research.She has served as the President for the International Society of Geriatric Oncology (2012–2014), and is currently serving as Chair of the NCCN Senior Adult Oncology Panel, co-Vice Chair of the Alliance Cancer in the Elderly Committee, and Editor-in Chief of the Journal of Geriatric Oncology. Dr. Hurria is also founder of the Cancer and Aging Research Group, a coalition that conducts multi-center geriatric oncology research studies and mentors junior faculty in geriatric oncology. She holds two R01 grants aimed at improving the care of older adults with cancer. In 2013, she received the ASCO B.J. Kennedy Award for Scientific Excellence in Geriatric Oncology.The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.Laura A. Levit, JD, is Associate Director of Research and Analysis in ASCO's Cancer Policy and Advocacy Department. She joined ASCO in January 2014 and has been working with the Cancer Research Committee to develop ASCO research statements and comment letters on topics including phase I trials, older adults' participation in research, obesity research, observational research, and clinical trial data sharing. Prior to joining ASCO, she was a program officer at the Institute of Medicine (IOM) where she served as the study director for the 2013 report “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis.” She also staffed multiple other projects with the IOM's Board on Health Care Services and the National Cancer Policy Forum. Ms. Levit graduated from the University of Virginia School of Law and is a member of the Virginia Bar Association. She completed her undergraduate studies at the College of William and Mary, receiving a BS with honors in psychology.
KumarASoaresHPBalducciLDjulbegovicB. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol2007;25:1272–1276.
KumarASoaresHPBalducciLDjulbegovicB. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. 2007;25:1272–1276.
Institute of Medicine: Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington, DC: National Academies Press; 2012.
Institute of Medicine: . Washington, DC: National Academies Press; 2012.
National Institutes of Health. S.1: National Institutes of Health Revitalization Act of 1993; Subtitle B—Clinical Research Equity Regarding Women and Minorities. Washington, DC: National Institutes of Health; 1993.
National Institutes of Health. . Washington, DC: National Institutes of Health; 1993.
HurriaALevitLADaleW. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement[published online ahead of print July 20 2015]. J Clin Oncolpii: JCO.2015.63.0319.
HurriaALevitLADaleW. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement[published online ahead of print July 20, 2015]. , pii: JCO.2015.63.0319.